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Background: Graves’ disease is one of the most common autoimmune conditions, but treatment remains
imperfect. This study explores the first-in-human use of antigen-specific immunotherapy with a combination of
two thyrotropin receptor (TSHR) peptides (termed ATX-GD-59) in Graves’ hyperthyroidism.
Methods: Twelve participants (11 female) with previously untreated mild to moderate Graves’ hyperthyroidism
were enrolled in a Phase I open label trial to receive 10 doses of ATX-GD-59 administered intradermally over
an 18-week period. Adverse events, tolerability, changes in serum free thyroid hormones, and TSHR auto-
antibodies were measured.
Results: Ten subjects received all 10 doses of ATX-GD-59, five (50%) of whom had free triiodothyronine
within the reference interval by the 18-week visit. Two further subjects had improved free thyroid hormones by
the end of the study (7/10 responders), whereas three subjects showed worsening thyrotoxicosis during the
study. Serum TSHR autoantibody concentrations reduced during the study and correlated with changes in free
thyroid hormones (r = 0.85, p = 0.002 for TSHR autoantibody vs. free triiodothyronine). Mild injection-site
swelling and pain were the most common adverse events.
Conclusions: These preliminary data suggest that ATX-GD-59 is a safe and well-tolerated treatment. The
improvement in free thyroid hormones in 70% of subjects receiving the medication suggests potential efficacy
as a novel treatment for Graves’ hyperthyroidism.
Keywords: peptide immunotherapy, Graves’ disease, autoimmune thyroid disease, desensitization, thyroid
stimulating hormone receptor, immunomodulation
Introduction
Graves’ disease (GD) is the most common cause ofhyperthyroidism, and results from the production of
autoantibodies that stimulate the cell-surface thyrotropin
receptor (TSHR) (1). It affects around 3% of women
and 0.5% of men over a lifetime, and most commonly
presents in the fourth and fifth decades of life, with a dis-
proportionate burden of ill health falling on working-age
women (2).
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There have been no new treatment options for hyperthy-
roid patients with GD for >60 years (3). At present, antithy-
roid drugs (ATD), mostly methimazole and its pro-drug
carbimazole, are the usual first-line treatment, with radioac-
tive iodine and total thyroidectomy reserved as second-line
therapies in most health-care environments (4). Each of these
therapeutic modalities has significant drawbacks, in particu-
lar that ATDs induce drug-free remission in only 50% of
people (5), and that both radioiodine and thyroidectomy re-
sult in lifelong hypothyroidism. In addition, there is a small
risk of agranulocytosis with ATDs, occurring in around
0.2–0.5% of patients (6,7). Many GD patients are also
apprehensive about the theoretical hazards of radioiodine
administration, and young patients are frequently keen to
avoid the risk of surgery and the anterior neck scar that
results from conventional thyroidectomy. These factors
mean that there is currently no ideal treatment for GD, and
that each patient makes a trade-off between the certainty of cure
and the different undesirable effects with each therapy (8).
Antigen-specific immunotherapy, administering small
amounts of antigens over time, often reinstates immune tol-
erance in allergy (9), but in autoimmune diseases, the ap-
proach has been associated with complications from immune
responses to the administered antigens (10–12). Over recent
years, it has been shown that the risk of an immune response
can be minimized during tolerance induction by the use
of synthetic peptides that mimic naturally processed CD4+
T-cell epitopes (13,14). Such peptides have been termed
‘‘apitopes,’’ short for antigen-processing independent epi-
topes (15). Apitopes have successfully induced self-tolerance
in multiple sclerosis (16), and the mixture of myelin basic
protein (MBP) peptides used (ATX-MS-1467) is currently in
Phase IIb development. A similar approach has also shown
preliminary evidence of efficacy in type 1 diabetes (17).
ATX-GD-59 is an admixture of two soluble, synthetic
peptides based on the sequence of the human TSHR that have
been shown to function as apitopes in HLA-DR3 transgenic
mice immunized with human TSHR (18). One peptide, 9B-N
(15 amino-acid residues), is an exact sequence found in
TSHR, whereas the other, 5D-K1 (21 amino-acid residues),
contains an amino-acid sequence found in the TSHR with the
addition and replacement of charged amino acids to the N-
and C-terminal flanks for increased solubility. Both peptides
overlap with residues previously documented as TSHR im-
munodominant T-cell epitopes in HLA-transgenic murine
models of GD (19,20). ATX-GD-59 is thought to bind with
high affinity to HLA-DR molecules on the surface of im-
mature dendritic cells in the draining lymph node without
prior internalization, thereby reducing the risk for activation
of antigen-presenting cells (18).
Here, the results from an open-label Phase I study to assess
the safety and biological activity of ATX-GD-59 in adult
subjects with Graves’ hyperthyroidism not currently treated
with antithyroid therapy are reported for the first time.
Methods
Study design
This was an open-label study conducted at eight National
Health Service endocrinology centers in the United King-
dom. The primary objective was to assess the safety and
tolerability of intradermal (i.d.) administration of ATX-GD-
59 in subjects with GD not currently treated with ATDs.
Secondary outcomes were to explore biological activity, in-
cluding changes in hormonal, immunological, and TSHR
antibody levels, with treatment. The study was designed in
full compliance with the ethical requirements set out in the
Declaration of Helsinki (21) and the International Conference
on Harmonisation (ICH), as well as with local regulations
(22). All subjects gave their written informed consent to
participate. The trial was registered with clinicaltrials.gov
(NCT02973802) and approved by the East of England (Es-
sex), Research Ethics Service (16/EE/0133). The full study
protocol is available at www.daviad.eu
Eligible subjects were between 18 and 65 years of age with
mild to moderately severe GD diagnosed by a physician
from clinical and laboratory findings, and none had received
prior treatment with ATD. Subjects had to carry at least one
major histocompatibility complex (MHC) class II HLA-
DRB1*15, HLA DRB1*03, or HLA DRB1*04 allele, and
have quantifiable levels of TSHR antibodies, elevated
levels of free triiodothyronine (fT3) and/or free thyroxine
FIG. 1. Time course, titration scheme, and visit schedule during the study.
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(fT4; not exceeding 15 pmol/L and 35 pmol/L, respec-
tively), and undetectable levels of thyrotropin (TSH) at
screening. These MHC allelotypes have been demonstrated to
bind the administered peptides (19). Men who were not sterile
and women of child-bearing potential had to commit to
birth-control measures. Main exclusion criteria were preg-
nancy or breastfeeding in women, treatment with any ATD,
steroids, or adrenocorticotropic hormone (with the exception
of inhaled steroids), or cytokine or anti-cytokine therapy
within the previous three months prior to study day 1, pre-
vious treatment with biological or peptide-based immu-
notherapy, previous treatment with radioiodine, partial or
complete thyroidectomy, or detectable levels of antibodies in
plasma specific for any of the peptides within ATX-GD-59.
Treatment with oral propranolol was permitted throughout
the study.
This was an open-label study in which all participants
received ATX-GD-59. The time course, titration sched-
ule, and visits are shown in Figure 1. ATX-GD-59 is a ly-
ophilized equimolar mixture of two peptides (peptide 5D-K1:
KKKKYVSIDVTLQQLESHKKK, and peptide 9B-N:
GLKMFPDLTKVYSTD) reconstituted at the clinic to
4 mg/mL and 0.5 mg/mL total peptide content, depending
on dose, prior to i.d. injection. The starting dose was 25 lg
i.d., and the maximum single dose was 800 lg, based on
other immunotherapy studies with apitopes (15,16,18), and
included a safety margin compared to doses used in repeat-
dose toxicity studies in a rodent model.
The first four subjects were recruited sequentially with a
minimum of 48 hours between the first dose of each subject.
Individual subject safety data were reviewed by the investi-
gator and the medical monitor after the first dose of ATX-
GD-59. Dosing of the remaining subjects only commenced
once the first subject has received the second dose without
safety concerns identified.
During an eight-week period, the dose was titrated bi-
weekly up to a final dose of 800 lg. Subjects were then
maintained on the full dose for 10 weeks, followed by a 12-
week safety and evaluation period off treatment.
Outcome measures
Data were gathered by site investigators and entered
into electronic case report forms for analysis. The primary
outcome measure was the occurrence of treatment-emergent
adverse events (TEAE), serious AE including treatment-
emergent serious adverse events (TESAE), and laboratory
abnormalities assessed on an ongoing basis up to week 22.
Secondary outcomes measures were serum fT3, fT4, and
TSH concentrations assayed at a central site (Roche, Centaur
platform; Quintiles/IQVIA, Livingston, United Kingdom).
Patients whose circulating thyroid hormone concentrations
(fT4 or fT3) reduced during the dosing period compared to
baseline measurements were designated as responders.
Changes in TSHR antibody levels measured by both a TSHR
antibody binding-inhibition assay (TBII; Cobas; Roche,
Basel, Switzerland) and by in vitro stimulation of a Chinese
FIG. 2. Patient flow (CONSORT). The asterisk indicates two screened subjects who were excluded on two counts: HLA
ineligible and fT4/fT3 values too high (n = 1) or too low (n = 1). ITT, intention to treat, PP, per protocol, ATD, antithyroid
drug; fT4, free thyroxine; fT3, free triiodothyronine.
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hamster ovary cell line expressing the TSHR (TSHR-
stimulating antibodies [TSAb] cell-based bioassay; Thyr-
etain, Quidel, San Diego, CA), as described (23), were also
exploratory secondary outcomes. The TSHR antibody mea-
surements were done at Johannes Gutenberg University
Medical Center (Mainz, Germany) (23).
Documentation of AEs and concomitant medications
All AEs were recorded at each clinic visit and character-
ized by severity and relationship to the study drug according
to Medical Dictionary for Regulatory Activities (MedDRA
19.1) terminology. The indication for the concomitant med-
ications was recorded along with the dose and the period of
therapy. During the dosing phase, subjects were observed in
the clinic for at least two hours after administration of the
study drug with regular monitoring of vital signs. Laboratory
hematology, clinical chemistry, and urinalysis safety mea-
surements were performed at all visits.
Statistical methods
Data are presented descriptively. Baseline, safety, and
efficacy data are presented for the primary intention to treat
(ITT) population, comprising all subjects who received one
or more doses of study drug. Means – standard deviation and
medians (min–max) are presented as appropriate; changes
from baseline are given as percentages. Correlations between
change in thyroid function tests and TRAb levels were ana-
lyzed using the parametric Pearson’s test. Outcome data were
analyzed for all participants who received the full 10 doses of
ATX-GD-59. For this Phase I study, no formal sample size
calculation was performed.
Results
Participant flow
Out of the 28 subjects screened, 12 were enrolled in the
study and received treatment. Due to enrolment time con-
straints, the estimated protocol target of 15 subjects was not
achieved. The flow of participants is shown in Figure 2. The
safety (ITT) population comprised 12 subjects who received
at least one dose of the study drug. Ten subjects completed
the study, and of these, eight received the treatment regimen
in full compliance with the protocol. Two subjects did not
complete the study, as one was lost to follow-up and the other
withdrew consent for non-safety reasons. One subject took
ATDs on the day of but after the final dose (at week 18). One
subject was unintentionally underdosed throughout the study.
One subject had elevated fT3 and fT4 concentrations at the
screening visit and was enrolled per protocol (PP), but the
concentrations were found to have returned to the reference
range following dosing at visit 1 (her TBII antibodies were
positive). One subject had asymmetrical upper eyelid re-
traction at baseline, but none had active Graves’ orbitopathy.
Demographic data of the safety population are shown in
Table 1. Of the 10 subjects who completed the full study dose
regimen, six received oral propranolol (40–160 mg daily)
during the study: three from before the first study visit and
three subsequently (at weeks 2, 4, and 7).
Safety results
A total of 11 subjects reported 311 TEAEs during
the study, of which 180 were considered treatment related.
A summary is provided in Table 2. Of the 311 TEAEs,
Table 1. Demographic Characteristics
of the Study Population at Screening
(ITT Population, n= 12)
Variable Value
Age (years), M– SD 42.7 – 9.7
Female sex, n (%) 11 (92%)
BMI (kg/m2), M– SD 28.0 – 5.1
Family history of Graves’ disease
at screening, n (%)
2 (17%)
fT3 (pmol/L), median (min–max),
ref: 3.5–6.5
9.3 (6.8–13.4)
fT4 (pmol/L), median (min–max),
ref: 11.5–22.7
24.2 (17.7–35.0)
TSH (mIU/L), median (min–max),
ref: 0.4–4.0
0.01 (0.01–0.02)
HLA typing (allele 1 and 2)
DRB1*03:01 8 (67%)
DRB1*04:0X 6 (50%)
DRB1*15:01 3 (25%)
Non-DRB1*03,*04, or *15 7 (58%)
Pre-dose TBII (IU/L), median
(min–max], cutoff: <1.75 IU/L
3.77 (1.84–15.66)
Pre-dose TSAb (%), median
(min–max), cut-off: SRR% <140%
406.0 (234–1052)
HLA DRB1*04:0X alleles include alleles *04:01 (n = 1), *04:02
(n= 3), *04:04 (n = 1), and *04:07 (n = 1). NB: To be eligible, only
one suitable HLA allele was required.
TSHR, thyrotropin receptor; TBII, TSHR-binding inhibitory
immunoglobulin; TSAb, stimulatory TSHR antibodies; SRR,
specimen-to-reference ratio.
Table 2. Most Frequent TEAEs
Number of subjects
(number of events)
Variable
Titration
period
overall
(N = 12)
Full
treatment
period,
800 lg
(N = 11)
TEAEs 11 (157) 10 (154)
Drug-related TEAEs 11 (93) 10 (87)
TESAEs 1 (1) 1 (2)
Drug-related TESAEs 1 (1) 0
TEAEs leading to death 0 0
TEAEs leading to early study
withdrawal
0 0
TEAEs leading to dose
interruption or
suspension
0 0
Treatment-emergent
intradermal injection–
related reaction
11 (74) 10 (79)
TEAEs by maximum
severity:
Mild 11 (150) 10 (143)
Moderate 5 (7) 5 (11)
Severe 0 0
TEAEs, treatment-emergent adverse events; TESAEs, treatment-
emergent serious adverse events.
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293 events were mild, and 18 events were moderate in
intensity. No severe AEs or deaths were reported. The
majority of treatment-related TEAEs were injection-site
reactions, the most common reported as erythema, swelling,
and pain, which accounted for 153 of all 180 treatment-related
TEAEs, and all were mild in severity. No TEAEs leading
to drug interruption, suspension, or early withdrawal were
reported. The remainder of the TEAEs included various
inconsistent minor conditions, including headache, nau-
sea, food poisoning, upper respiratory tract, skin, and
fungal nail infections. There was no discernible difference
between the frequency of study drug–related AEs between
the titration period and the full-dose treatment period
(Table 2).
A single subject experienced three TESAEs on different
occasions: nausea (moderate intensity, possibly related to
drug), vomiting (mild intensity, not related to drug), and
atrial fibrillation (mild intensity, not related to drug). For
each of these AEs, the categorization as serious was based
on new or prolonged hospitalization for observation. An-
other subject developed first-degree heart block at week 4,
which improved when concomitant propranolol was dis-
continued. One subject tested positive for antidrug anti-
bodies at week 14 and remained positive at week 22. There
were no accompanying clinical sequelae.
Efficacy results
The absolute levels of serum fT3 and fT4 for each subject
are shown in Figure 3. Two subjects did not complete the
full dosing schedule, discontinuing treatment following one
and six doses. Of 10 participants completing follow-up, five
(50%) had fT3 within the reference range following the 10
doses of ATX-GD-59, including one subject who was un-
derdosed with the study medication; a further two subjects
had lower serum fT3 and fT4 concentrations at 18 weeks
than at baseline (making 7/10 subjects with a total or partial
response). Two participants had detectable serum TSH at
week 18—one 0.11 mIU/L and the other 2.56 mIU/L—with
the remaining subjects’ TSH concentrations remaining
at £0.02 mIU/L. Three subjects had small but progressive
elevations in fT3 and fT4 over the same time period. No
subject required intervention with ATDs during the 18-
week dosing period, but one subject received carbimazole
following the final dose of ATX-GD-59 at week 18 and a
second following the week 22 assessment (shown as dashed
lines in Fig. 3). Two of the three non-responders and four of
seven responders took propranolol during the active treat-
ment phase. Two patients remained euthyroid without
ATDs for a year after their last dose of peptides; one became
transiently hypothyroid.
FIG. 3. Individual levels of
fT3 (A) and fT4 (B) over
time in the ITT population.
Blue lines represent re-
sponders, defined as those
who showed a reduction in
levels of both fT3 and fT4 at
week 18. The dotted blue line
indicated with a dagger rep-
resents one subject who was
underdosed. This subject also
received ATDs after week
22. Red lines represent non-
responders. The dotted red
line indicated by an asterisk
represents one subject who
received ATDs after week
18. Fields shaded yellow in-
dicate reference ranges.
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Overall, there were reductions in both TBII and TSAb
concentrations across the participant cohort over the study
period, but they remained elevated in most subjects (Fig. 4).
There were significant correlations between changes in se-
rum fT3 concentration and changes in both TBII and TSAb
from baseline to week 18 ( p = 0.002 and p = 0.02, respec-
tively; see Supplementary Fig. S1). Reduction in serum fT4
was also associated with falling TBII levels ( p = 0.03), with
a similar trend toward association with TSAb concentration
( p = 0.11).
Discussion
Hyperthyroidism in GD presents as a consequence of the
direct effects of stimulating TSHR autoantibodies on thyroid
function, rather than because of prolonged tissue damage or
inflammation. Thus, unlike type 1 diabetes or Addison’s
disease, where it is estimated that 80–90% of the relevant
functional endocrine tissue has already been destroyed before
symptoms of hormonal deficiency occur (24,25), GD may
present more quickly in relation to the evolving immune re-
sponse. This means that GD may be particularly amenable to
immunotherapeutic approaches, as the immune response may
be less well established in GD than in other autoimmune
conditions. Furthermore, the underlying hormone-producing
tissue is not destroyed, leaving the opportunity for normal
function in the future if the immune response can be modified
or abrogated.
The extracellular domain (ECD) of the TSHR is very well
characterized as the target of both the humoral and cell-
mediated autoimmune responses in GD (26), and preclinical
work on small-molecule ‘‘drug-like’’ ligands acting as TSHR
agonists has helped yield important insights in the patho-
physiology of disease (27). The current work is the first study
to target the anti-TSHR autoimmune process specifically in
humans. The treatment, consisting of a mixture of two sol-
uble TSHR ECD peptides, which was administered 10 times
to each participant over 18 weeks by i.d. injection, appears to
be safe, with mild injection-site swelling and pain as the most
frequent AEs. The treatment was also well tolerated, with 10/
12 participants finishing the study, despite the requirement
for a two-hour in-hospital observation period following each
dose. In addition, 7/10 subjects had improvement in their
thyroid function over the 18 weeks of ATX-GD-59, with five
(50%) normalizing their serum fT3 concentrations, which is
the most sensitive serum marker of hyperthyroidism in this
context. In concert with reductions in free thyroid hormones,
serum TSHR autoantibodies also reduced, and these corre-
lated with improvement in hyperthyroidism. While falling
short of a formal demonstration of efficacy in this first-in-
FIG. 4. Individual levels of
thyrotropin receptor (TSHR)
antibodies, measured as (A)
TSHR binding inhibitory
immunoglobulin (TBII) and
(B) TSHR stimulatory anti-
bodies (TSAb). Blue lines
represent responders. The
dotted blue line indicated
with a dagger represents one
subject who was underdosed.
This subject also received
ATD after week 22. Red
lines represent non-
responders. The dotted red
line indicated by an asterisk
represents one subject who
received ATDs after week
18. Thresholds for positive
antibody concentrations are
1.75 IU/L for TBII and 140%
for TSAb, shown as yellow-
shaded fields.
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human study, these early results suggest that ATX-GD-59
may have a significant disease-modifying therapeutic effect
in GD.
During the design of the study, evidence of the potential
therapeutic efficacy of ATX-GD-59 was sought, without
confounding the assessment of thyroid function by co-
administration of ATDs. For this reason, a decision was made
to include participants who were relatively mildly affected by
hyperthyroidism (inclusion criteria serum fT3< 15 pmol/L,
fT4 < 35 pmol/L) and who might have few symptoms and a
low risk of complications from thyrotoxicosis during the
study. While this was a successful strategy, in that no patient
needed ATD rescue therapy for symptomatic thyrotoxicosis
before the final dose of ATX-GD-59, it does mean that these
results should be considered as most relevant to GD patients
with mild to moderate thyrotoxicosis at the moment. An-
other key issue is the potential for spontaneous remission of
GD. McLarty et al. reported spontaneous remission of
Graves’ hyperthyroidism in 2/21 patients treated with pro-
pranolol over a six-month period (28). Subsequently, other
studies have observed spontaneous remission in between
10% and 25% of GD patients treated with propranolol alone
during three to eight months of treatment (29,30). Thus, the
finding of improvement in hyperthyroidism in 7/10 subjects
and of normalization of fT3 in five ATX-GD-59-treated
subjects is above what would be predicted from sponta-
neous remission alone. Nevertheless, a formal proof of
efficacy study using a placebo-controlled design is needed
to confirm this.
GD is one of the commonest autoimmune disorders, and
none of the current treatment options are ideal. In particular,
ATDs are effective in producing long-term remission in
only 50% of patients, and both thyroidectomy and radio-
iodine therapy lead to long-term medication dependence.
Additionally, Graves’ orbitopathy affects up to 40% of pa-
tients, and current management is unsatisfactory, with a
significant minority being left with residual visual impair-
ment, diplopia, or disfiguring changes to the appearance of
their eyes. Emerging antigen-specific immunotherapies
such as ATX-GD-59 hold several theoretical attractions for
treatment of autoimmune, inflammatory, and allergic dis-
eases (15–17,31). As these therapies are directed solely at
restoring immune tolerance to the immunodominant epi-
topes involved in the aberrant autoimmune response, they
do not cause generalized immunosuppression with the as-
sociated risk of infection, nor do they skew the immune
response, putting the patient at risk of different immune-
mediated conditions. Notably, cases of immune complex–
mediated arthralgia and inflammatory bowel disease have
been reported in GD patients following treatment with B-
lymphocyte-depleting monoclonal antibodies (32). Fur-
thermore, GD is a particularly attractive model, since if
immune tolerance can be restored, the underlying thyroid
endocrine function is likely to remain intact for many years,
meaning patients have the potential for effective long-term
cure. Patients with significant Graves’ orbitopathy were
excluded from the current study. However, as there is a
significant correlation between the development and se-
verity of orbitopathy and TSHR autoantibody concentra-
tions (33,34), it is possible that ATX-GD-59 or a similar
TSHR peptide combination could prove efficacious in this
most challenging condition. Future studies of ATX-GD-59
in both hyperthyroid GD and Graves’ orbitopathy patient
cohorts are now required to understand its full therapeutic
potential.
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